Wart Market Potential

The market opportunity for common warts is substantial, with approximately 22 million patients in the U.S. alone and no FDA-approved therapies currently available. If YCANTH is successfully developed, approved, and commercialized, it could represent a multibillion-dollar commercial opportunity for Verrica.